Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis
- PMID:1757610
- DOI: 10.1016/0190-9622(91)70318-v
Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis
Abstract
In two double-blind, parallel-group, multicenter trials, 0.05% halobetasol propionate cream was compared with 0.05% clobetasol 17-propionate cream and 0.05% betamethasone dipropionate cream in 264 patients with acute, severe exacerbations of atopic dermatitis. The efficacy of halobetasol propionate cream and betamethasone dipropionate cream was similar with regard to the success rate, as indicated by ratings of "healed" and "marked improvement" (88% versus 90%) and by an onset of therapeutic effect within 3 days of the start of treatment (40% versus 39%). The efficacy of halobetasol propionate cream and clobetasol 17-propionate cream was also similar with regard to success rates (89% versus 93%) and an onset of therapeutic effect within 3 days of the start of treatment (41% versus 38%). All three creams were well tolerated. Dryness of the skin and itching at the site of application were the reported adverse effects. Treatment was discontinued because of severe dryness of the skin in 1 of the 121 patients treated with halobetasol propionate cream and in 1 of the 59 patients treated with betamethasone dipropionate cream.
Similar articles
- A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis.Mensing H, Korsukewitz G, Yawalkar S.Mensing H, et al.J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1149-52. doi: 10.1016/0190-9622(91)70314-r.J Am Acad Dermatol. 1991.PMID:1757606Clinical Trial.
- Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis.Herz G, Blum G, Yawalkar S.Herz G, et al.J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1166-9. doi: 10.1016/0190-9622(91)70319-w.J Am Acad Dermatol. 1991.PMID:1757611Clinical Trial.
- A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus.Datz B, Yawalkar S.Datz B, et al.J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1157-60. doi: 10.1016/0190-9622(91)70316-t.J Am Acad Dermatol. 1991.PMID:1757608Clinical Trial.
- Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate.Yawalkar S, Wiesenberg-Boettcher I, Gibson JR, Siskin SB, Pignat W.Yawalkar S, et al.J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1137-44. doi: 10.1016/0190-9622(91)70312-p.J Am Acad Dermatol. 1991.PMID:1757603Review.
- Vitamin D and topical therapy.Lebwohl M.Lebwohl M.Cutis. 2002 Nov;70(5 Suppl):5-8.Cutis. 2002.PMID:12467332Review.
Cited by
- Topical anti-inflammatory treatments for eczema: network meta-analysis.Lax SJ, Van Vogt E, Candy B, Steele L, Reynolds C, Stuart B, Parker R, Axon E, Roberts A, Doyle M, Chu DK, Futamura M, Santer M, Williams HC, Cro S, Drucker AM, Boyle RJ.Lax SJ, et al.Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015064. doi: 10.1002/14651858.CD015064.pub2.Cochrane Database Syst Rev. 2024.PMID:39105474Free PMC article.Review.
- Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses.Feldman SR.Feldman SR.Curr Ther Res Clin Exp. 2005 May;66(3):154-71. doi: 10.1016/j.curtheres.2005.06.010.Curr Ther Res Clin Exp. 2005.PMID:24672120Free PMC article.Review.
- Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, Bergman JN, Chamlin SL, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Feldman SR, Hanifin JM, Margolis DJ, Silverman RA, Simpson EL, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R.Eichenfield LF, et al.J Am Acad Dermatol. 2014 Jul;71(1):116-32. doi: 10.1016/j.jaad.2014.03.023. Epub 2014 May 9.J Am Acad Dermatol. 2014.PMID:24813302Free PMC article.
- The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.Bashrahil B, Alzahrani Z, Samarkandy S, Aman A, Jfri A.Bashrahil B, et al.Front Med (Lausanne). 2023 Jan 16;9:1091271. doi: 10.3389/fmed.2022.1091271. eCollection 2022.Front Med (Lausanne). 2023.PMID:36726353Free PMC article.
- Strategies for using topical corticosteroids in children and adults with eczema.Lax SJ, Harvey J, Axon E, Howells L, Santer M, Ridd MJ, Lawton S, Langan S, Roberts A, Ahmed A, Muller I, Ming LC, Panda S, Chernyshov P, Carter B, Williams HC, Thomas KS, Chalmers JR.Lax SJ, et al.Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013356. doi: 10.1002/14651858.CD013356.pub2.Cochrane Database Syst Rev. 2022.PMID:35275399Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources